Glucagon-like receptor-1 agonists and impotence: A meta-analysis
World Journal of Methodology · 20.09.2026 · 16 (3)
DOI: 10.5662/wjm.119385 ↗Kurz gefasst
Metaanalyse in der Zeitschrift World Journal of Methodology, online erschienen am 20.09.2026. Verfasst von Hyder Osman Mirghani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Faculty of Medicine, University of Tabuk, Tabuk 51941, Saudi Arabia. s.hyder63@hotmail.com. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND Glucagon-like peptide receptors-1 agonists (GLP-1 agonists) have revolutionized the treatment of obesity and diabetes due to their potent effects on weight and glycemic control, and cardiorenal protection. However, emerging reports and post-marketing surveillance have raised concerns regarding erectile dysfunction (ED) or impotence in a subset of male patients. AIM To assess the association between GLP-1 agonists, ED, total (TT) and free testosterone (FT), sex hormone binding globulins (SHBG), luteinizing hormone (LH), and follicular stimulating hormone (FSH). METHODS We systematically searched PubMed, Google Scholar, and Web of Science in November and December 2026 for articles examining the association between GLP-1 agonists and ED, with no publication date restriction. However, only articles published in the English language were eligible. The terms used were GLP-1 agonists, ED, semaglutide, liraglutide, ozympic, tirzepatide, dulaglutide, and Impotence. RESULTS One hundred seventy-two articles were found; after removing duplicates, 63 remained, of which 12 full texts were screened, and 7 studies were included in the final meta-analysis. Seven studies involving 237 males were included. GLP-1 agonist therapy improved ED score with a significant statistical difference, MD = 2.73, 95% confidence interval (CI): 1.64-3.83. A significant increase was found regarding TT, SHBG, and FSH, MD 73.04, 95%CI: 16.91-129.17, MD 7.00, 95%CI: 1.71-12.30, and MD 0.46, 95%CI: 0.01-0.91 respectively. CONCLUSION No significant differences were evident regarding the FT, and LH. GLP-1 agonists significantly improved ED, TT, SHBG, and FSH in males, no effects were observed on FT, and LH; larger randomized trials are needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine, Faculty of Medicine, University of Tabuk, Tabuk 51941, Saudi Arabia. s.hyder63@hotmail.com.
- Internal Medicine, Faculty of Medicine, University of Tabuk, Tabuk 51941, Saudi Arabia.
Zitieren
APA
Mirghani, H. O., & AlQurashi, A. M. (2026). Glucagon-like receptor-1 agonists and impotence: A meta-analysis. World Journal of Methodology, 16(3). https://doi.org/10.5662/wjm.119385
Vancouver
Mirghani HO, AlQurashi AM. Glucagon-like receptor-1 agonists and impotence: A meta-analysis. World Journal of Methodology. 2026;16(3). doi:10.5662/wjm.119385
BibTeX
@article{Mirghani2026,
author = {Mirghani, Hyder Osman and AlQurashi, Asawir Mohammed},
title = {Glucagon-like receptor-1 agonists and impotence: A meta-analysis},
journal = {World Journal of Methodology},
year = {2026},
volume = {16},
number = {3},
doi = {10.5662/wjm.119385}
}
EUVIMED